Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).
Citing Iqvia data, Mylan observed that the rivastigmine transdermal system in the three doses had US sales of approximately US$248...



